SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to financial results for the second quarter and half year ending September 30th, 2021.02-11-2021
02-11-2021
Q2FY22 Quarterly Result Announced for Sun Pharmaceutical Industries Ltd.
Highlights: Consolidated sales from operations at Rs. 95,567 million, growth of 13% over Q2 last year India sales at Rs. 31,878 million, up 26% over same quarter last year US finished dosage sales at US$ 361 million, growth of 8% over Q2 last year Emerging Markets sales at US$ 243 million, up by 16% over Q2 last year Rest of World sales at US$ 188 million, up by 5% over same quarter last year R&D; investments at Rs. 5,364 million compared to Rs. 6,127 million for Q2FY21 EBITDA at Rs. 25,608 million, up by 21% over Q2 last year, with resulting EBITDA margin of 26.8% Net profit for the quarter was at Rs. 20,470 million, up 29% compared to adjusted net profit of Q2 last year and up 13% versus reported net profit YoY Consolidated sales from operations at Rs. 192,262 million, growth of 20% over same period last year. India sales at Rs. 64,961 million, up by 32% over H1 last year. US finished dosage sales at US$ 741 million up by 20% over H1 last year. Emerging Markets sales at US$ 461 million up by 20% over H1 last year. Rest of World sales at US$ 373 million, up by 18% over H1 last year. EBITDA at Rs. 53,325 million up 38% over H1 last year, with resulting EBITDA margin of 27.7%. Excluding the exceptional items, adjusted net profit for H1FY22 was at Rs. 40,263 million, up 47% YoY. Reported net profit for H1FY22 was at Rs. 34,912 million compared to Rs. 1,572 million for H1 last year. Dilip Shanghvi, Managing Director of the Company said, “Following our good Q1 performance, we have sustained the positive momentum in Q2 with a topline growth of 13% YoY, driven by a broad-based growth across multiple geographies. Our global specialty business has grown by 43% over Q2 last year. Ilumya has grown both YoY and sequentially. Our India business continues to do well with a growth of 26% YoY. We remain steadfast in our focus on growing our overall business and simultaneously strengthening our global specialty portfolio. The recent launch of Winlevi in US and Ilumya in Canada is a step forward in this direction.” Result PDF02-11-2021
Sun Pharmaceutical Industries Ltd - 524715 - Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2021
The Board of Directors of the Company at its meeting held today i.e. November 02, 2021 has inter alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2021. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we enclose herewith the following as 'Annexure': a) Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2021. b) Limited Review Report of the Statutory Auditors of the Company on Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2021. The meeting of the Board of Directors of the Company commenced at 10:30 a.m. and concluded at 01:10 p.m.02-11-2021
Sun Pharmaceutical Industries Ltd - 524715 - Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2021
The Board of Directors of the Company at its meeting held today i.e. November 02, 2021 has inter alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2021. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we enclose herewith the following as 'Annexure': a) Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2021. b) Limited Review Report of the Statutory Auditors of the Company on Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2021. The meeting of the Board of Directors of the Company commenced at 10:30 a.m. and concluded at 01:10 p.m.02-11-2021
Sun Pharma launches acne treatment cream Winlevi in US market
A first-in-class topical androgen receptor inhibitor, Winlevi was approved by the US Food and Drug Administration (FDA) in August 2020.01-11-2021
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to announcement of WINLEVI's availability in US.01-11-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 29, 2021 for Shanghvi Finance Pvt Ltd29-10-2021
Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 28, 2021 for Shanghvi Finance Pvt Ltd28-10-2021
Sun Pharma launches drug to treat plaque psoriasis in Canada
The company said ILUMYA has already completed a five-year study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis28-10-2021
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to announcement of ILUMYA's availability in Canada28-10-2021